共 70 条
[1]
Wanebo HJ(1993)Contribution of serum inhibitory factors and immune cellular defects to the depressed cell-mediated immunity in patients with head and neck cancer Am J Surg 166 389-394
[2]
Blackinton D(2008)D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer N Engl J Med 359 453-462
[3]
Kouttab N(2012)Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial Lancet 379 315-321
[4]
Sasako M(2001)Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 725-730
[5]
Sano T(2006)Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 11-20
[6]
Yamamoto S(2007)Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810-1820
[7]
Bang YJ(1981)The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification Jpn J Surg 11 127-139
[8]
Kim YW(2001)Risk factors for lymph node metastases and their prognostic significance in early gastric cancer (EGC) for the Italian Research Group for Gastric Cancer (IRGGC) Jpn J Clin Oncol 31 495-499
[9]
Yang HK(1998)Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study Ann Surg 228 449-461
[10]
Macdonald JS(2007)Prognostic significance of perinodal extension in gastric cancer J Surg Oncol 95 540-545